Survival Analysis of Adult Patients with Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy: Results of a Mexican National AML Registryacute myeloid leukemiaintensive chemotherapyregistryMexicoAMLThe outcome of patients with AML treated with intensive chemotherapy has improved, reaching long-...
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336. Article CAS Google Scholar ...
1. 2023ASH: 2896 Compared to Venetoclax Plus Hypomethylating Agents, High Dose Cytarabine Based Intensive Chemotherapy Induction for Newly Diagnosed Acute Myeloid Leukemia (AML) Leads to a Faster Remission Resulting in Better Survival. 2...
AML-068- Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but ... AML-068- Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and ...
Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994; 73: 1–7. Article CAS Google Scholar Haferlach T, Kohlmann A, Schnittger S, Dugas M, Hiddemann W, Kern W et al. Global ...
Investigates the relevance of in vitro leukemia cell survival to the overall survival of patients with acute myeloid leukemia (AML) using MTT-assay. Absence of correlation of leukemia cell survival and Bcl-2 expression; Association of growth factor withdrawal with rapid onset of cellular apoptosis.被...
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with a dismal 5-year survival rate of only 24%. This prognosis is even worse in refractory or relapsed (R/R) patients, where the 5-year survival rate falls below 10% [1]. Given these bleak statistics,...
The phase 1 study of HEMO-CAR-T in patients with acute myeloid leukemia can proceed following the lifted clinical hold. CAR T-cell attack cancer cell and healthy cells © LASZLO - stock.adobe.com HEMO-CAR-T is a proprietary chimeric antigen receptor (CAR) T-cell therapy. The agent is...
Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: Evidence from four decades of US population data. Cancer Epidemiol. 2015;39(5):720-726.Hossain MJ, Xie L and Caywood EH: Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: ...
急性髓系白血病(AML)是成人白血病最常见的类型,其治疗包括诱导、巩固、维持、拯救治疗和造血干细胞移植。传统“3+7”强化疗(IC)方案是新诊断适合化疗AML患者的标准治疗方案,异基因造血干细胞移植(allo-HSCT)是高危AML患者的重要治疗手段。但是近50年来,AML的总生存率改善不明显,诱导治疗早期死亡(死亡率约20%1)和...